Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product
Year: 2021
Type: article
Institutions: Northside Hospital, Massachusetts General Hospital, City Of Hope National Medical Center, City of Hope, University of Nebraska Medical Center, Fred Hutch Cancer Center, University of Colorado Cancer Center, Bristol-Myers Squibb (United States), Juno Therapeutics (United States), Memorial Sloan Kettering Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W3126315276